Highlight
At the 2025 American Diabetes Association (ADA) Scientific Sessions, several pivotal studies presented promising advances in obesity and diabetes management. Key highlights include the introduction of CagriSema, a dual agonist combining semaglutide and cagrilintide, which demonstrated superior weight loss compared to monotherapy. The BELIEVE trial revealed a novel combination of semaglutide with bimagrumab that promotes fat mass loss while preserving lean muscle. The SOUL trial confirmed cardiovascular benefits of oral semaglutide in high-risk type 2 diabetes patients. Additionally, the PATHWEIGH care model optimized obesity management in primary care. In pediatric type 1 diabetes, inhaled insulin showed noninferior glycemic control with less weight gain and higher patient satisfaction. Finally, a randomized trial demonstrated that switching from diet beverages to water significantly enhanced weight loss and diabetes remission in women with type 2 diabetes undergoing weight management.
Obesity and type 2 diabetes mellitus (T2DM) remain major global health challenges, contributing to increased cardiovascular and renal morbidity and mortality. Weight management is central to improving glycemic control and reducing complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized treatment by promoting weight loss and cardiovascular benefits. However, adverse effects such as muscle loss and patient reluctance toward injectable therapies limit their uptake. Moreover, lifestyle interventions including dietary modifications remain foundational but challenging to sustain. In pediatric type 1 diabetes (T1DM), optimizing insulin delivery to improve adherence and minimize side effects like weight gain is critical. The integration of novel pharmacologic agents with practical care models and lifestyle strategies is imperative to address these unmet needs.
